Nasdaq

Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary ...
Nasdaq

Bicycle Therapeutics' BT8009 Gets FDA Fast Track Designation To Treat Urothelial Cancer

(RTTNews) - Bicycle Therapeutics plc (BCYC) announced Wednesday that the U. S. Food and Drug Administration has granted Fast Track Designation or FTD to its BT8009 monotherapy to treat adult patients ...